The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. [electronic resource]
Producer: 20130219Description: e42863 p. digitalISSN:- 1932-6203
- Antineoplastic Agents -- pharmacology
- Benzamides
- Blast Crisis -- drug therapy
- Cell Cycle Proteins -- genetics
- Cyclin B1 -- genetics
- Drug Resistance, Neoplasm -- drug effects
- Endopeptidases -- genetics
- Fusion Proteins, bcr-abl -- genetics
- Genomic Instability -- drug effects
- HL-60 Cells
- Humans
- Imatinib Mesylate
- K562 Cells
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Neoplasm Proteins -- genetics
- Phosphorylation -- drug effects
- Piperazines -- pharmacology
- Protein Phosphatase 2 -- genetics
- Proteolysis
- Pyrimidines -- pharmacology
- Securin
- Separase
- U937 Cells
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.